Peak6 LLC Purchases Shares of 31,884 Enovis Co. (NYSE:ENOV)

Peak6 LLC acquired a new position in Enovis Co. (NYSE:ENOV) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 31,884 shares of the company’s stock, valued at approximately $1,399,000.

Other hedge funds have also recently made changes to their positions in the company. FMR LLC lifted its position in shares of Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after purchasing an additional 484 shares in the last quarter. Barclays PLC grew its stake in shares of Enovis by 16.1% in the third quarter. Barclays PLC now owns 368,488 shares of the company’s stock worth $15,864,000 after acquiring an additional 51,151 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Enovis by 9.5% during the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company’s stock worth $39,678,000 after acquiring an additional 80,165 shares during the period. Retirement Systems of Alabama raised its stake in shares of Enovis by 10.1% in the third quarter. Retirement Systems of Alabama now owns 67,846 shares of the company’s stock valued at $2,921,000 after acquiring an additional 6,239 shares in the last quarter. Finally, Confluence Investment Management LLC purchased a new position in Enovis in the fourth quarter valued at $3,494,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

ENOV stock opened at $31.91 on Friday. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -14.57 and a beta of 1.86. Enovis Co. has a fifty-two week low of $29.32 and a fifty-two week high of $56.89. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The business has a 50 day moving average price of $37.53 and a 200 day moving average price of $42.17.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Equities research analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of Enovis in a research report on Wednesday, April 9th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.